Revumenib is under clinical development by Syndax Pharmaceuticals and currently in Phase II for Relapsed Acute Myeloid Leukemia. According to GlobalData, Phase II drugs for Relapsed Acute Myeloid Leukemia have a 20% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Revumenib’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
SNDX-5613 is under development for the treatment of genetically-defined subset of acute leukemias with chromosomal rearrangements in the MLL gene such as relapsed and refractory acute lymphoblastic leukemia, acute myelobalstic leukemia and unresectable metastatic microsatellite stable colorectal cancer. It is administered orally. The drug candidate acts by targeting interaction of menin with the mixed lineage leukemia (MLL) protein and by inhibiting nucleophosmin (NPM1).
Syndax Pharmaceuticals overview
Syndax Pharmaceuticals (Syndax) is a biopharmaceutical company that discovers, develops and commercializes therapies for multiple cancer indications. The company’s product portfolio includes SNDX-5613, a novel orally menin-MLL1 inhibitor used for the treatment of MLLr or mNPM1 acute leukemias; and SNDX-6352 (Axatilimab), a colony stimulating factor 1 receptor (CSF-1R) to treat chronic graft versus host disease (cGVHD). It is also evaluating entinostat (SNDX-275), a class I HDAC inhibitor against multiple solid tumors. Syndax product candidate are also used for the treatment of non-small cell lung cancer and melanoma, ovarian cancer and other indications. The company has an operational presence in the UK. Syndax is headquartered in Waltham, Massachusetts, the US.
For a complete picture of Revumenib’s drug-specific PTSR and LoA scores, buy the report here.